-
EP3064511
European procedure
Extract from the Register of European Patents
EP About this file: EP3064511
| EP3064511 - MEDICAL USE OF HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR [Right-click to bookmark this link] | |||
| Former [2016/36] | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR | ||
| [2017/47] | Status | No opposition filed within time limit Status updated on 22.02.2019 Database last updated on 27.05.2026 | |
| Former | The patent has been granted Status updated on 16.03.2018 | ||
| Former | Grant of patent is intended Status updated on 01.11.2017 | ||
| Former | Request for examination was made Status updated on 10.02.2017 | Most recent event Tooltip | 22.02.2019 | No opposition filed within time limit | published on 27.03.2019 [2019/13] | Applicant(s) | For all designated states Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591 / US | [2016/36] | Inventor(s) | 01 /
PAPADOPOULOS, Nicholas J 59 Heritage Lane Lagrangeville New York, NY 12540 / US | 02 /
FAIRHURST, Jeanette L 23 Parkview Court White Plains, NY 10603 / US | 03 /
HUANG, Tammy T 28 Gideon Reynolds Road Cross River, NY 10518 / US | 04 /
MARTIN, Joel H 244 Church Road Putnam Valley, NY 10579 / US | [2016/36] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2018/16] | J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | ||
| Former [2016/36] | Power, David J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 16161244.5 | 27.10.2009 | [2016/36] | Priority number, date | US20080260307 | 29.10.2008 Original published format: US 260307 | [2016/36] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3064511 | Date: | 07.09.2016 | Language: | EN | [2016/36] | Type: | B1 Patent specification | No.: | EP3064511 | Date: | 18.04.2018 | Language: | EN | [2018/16] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 25.07.2016 | Classification | IPC: | C07K16/28, A61P37/08 | [2016/36] | CPC: |
C07K16/2866 (EP,CN,RU,US);
A61K39/3955 (RU,US);
C07K16/28 (KR);
A61K39/395 (KR);
A61K45/06 (RU,US);
A61P1/04 (EP);
A61P11/00 (EP);
A61P11/06 (EP);
A61P13/08 (EP);
A61P13/12 (EP);
A61P15/00 (EP);
A61P17/00 (EP);
A61P17/02 (EP);
A61P17/04 (EP);
A61P19/02 (EP);
A61P25/08 (EP);
A61P29/00 (EP);
A61P31/04 (EP);
A61P31/06 (EP);
A61P35/00 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
A61P37/06 (EP);
A61P37/08 (EP);
A61P43/00 (EP);
A61P7/00 (EP);
A61P7/06 (EP);
A61K2039/505 (EP,CN,US);
C07K2317/21 (EP,CN,US);
C07K2317/565 (CN);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2017/11] |
| Former [2016/36] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR | Extension states | AL | 06.02.2017 | BA | 06.02.2017 | RS | 06.02.2017 | Title | German: | MEDIZINISCHE VERWENDUNG VON MENSCHLICHEN ANTIKÖRPERN MIT HOHER AFFINITÄT FÜR DEN MENSCHLICHEN IL-4-REZEPTOR | [2017/47] | English: | MEDICAL USE OF HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR | [2017/47] | French: | UTILISATION MÉDICALE DE ANTICORPS HUMAINS A HAUTE AFFINITE DU RECEPTEUR IL-4 HUMAIN | [2017/47] |
| Former [2016/36] | MENSCHLICHE ANTIKÖRPER MIT HOHER AFFINITÄT FÜR DEN MENSCHLICHEN IL-4-REZEPTOR | ||
| Former [2016/36] | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR | ||
| Former [2016/36] | ANTICORPS HUMAINS A HAUTE AFFINITE DU RECEPTEUR IL-4 HUMAIN | Examination procedure | 18.03.2016 | Date on which the examining division has become responsible | 06.02.2017 | Examination requested [2017/11] | 13.04.2017 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 21.06.2017 | Amendment by applicant (claims and/or description) | 02.11.2017 | Communication of intention to grant the patent | 01.03.2018 | Fee for grant paid | 01.03.2018 | Fee for publishing/printing paid | 01.03.2018 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP09744292.5 / EP2356151 | EP12175412.1 / EP2511300 | EP13163791.0 / EP2636685 | Divisional application(s) | EP18158965.6 / EP3351560 | EP20162800.5 / EP3715372 | EP23216315.4 | Opposition(s) | 21.01.2019 | No opposition filed within time limit [2019/13] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 21.06.2017 | Request for further processing filed | 21.06.2017 | Full payment received (date of receipt of payment) Request granted | 04.07.2017 | Decision despatched | Fees paid | Renewal fee | 18.03.2016 | Renewal fee patent year 03 | 18.03.2016 | Renewal fee patent year 04 | 18.03.2016 | Renewal fee patent year 05 | 18.03.2016 | Renewal fee patent year 06 | 18.03.2016 | Renewal fee patent year 07 | 11.10.2016 | Renewal fee patent year 08 | 23.10.2017 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] WO2008054606 (REGENERON PHARMA et al.) | [A] WO0192340 (IMMUNEX CORP et al.) | [A] WO2005047331 (IMMUNEX CORP et al.) | by applicant | US5599905 | US5767065 | US5840869 | US5717072 | US7186809 | US6949245 | WO9402602 | US6596541 | US5714146 | US5985280 | US6716587 | US5545807 | US6787637 | US2004101920 | US2007280945 | REDDY ET AL., J. IMMUNOL., vol. 164, 2000, pages 1925 - 1933 | SHIELD ET AL., JBC, vol. 277, 2002, pages 26733 | WARD ET AL., NATURE, vol. 241, 1989, pages 544 - 546 | BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426 | HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883 | HOLLIGER ET AL., PROC. NATL. ACAD SCI. USA, vol. 90, 1993, pages 6444 - 6448 | PEARSON, METHODS MOL. BIOL., vol. 24, 1994, pages 307 - 331 | GONNET, SCIENCE, vol. 256, 1992, pages 1443 - 1445 | ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 | ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 402 | GREEN ET AL., NATURE GENETICS, vol. 7, 1994, pages 13 - 21 | HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY | MALIK; LILLEHOJ: "Antibody Techniques", 1994, ACADEMIC PRESS | ANGAL ET AL., MOLECULAR IMMUNOLOGY, vol. 30, 1993, pages 105 | REINEKE, METHODS MOL BIOL, vol. 248, 2004, pages 443 - 63 | TOMER, PROTEIN SCIENCE, vol. 9, 2000, pages 487 - 496 | TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60 - 69 | "Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY | POWELL ET AL.: "Compendium of excipients for parenteral formulations", J PHARM SCI TECHNOL, vol. 52, 1998, pages 238 - 311 | WU ET AL., J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432 | LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533 | TREAT ET AL.: "Liposomes in the Therapy of Infectious Disease and Cancer", 1989, LISS, pages: 353 - 365 | LOPEZ-BERESTEIN: "LIPOSOMES IN THE THERAPY OF INFECTIOUS DISEASE ANS CANCER", pages: 317 - 327 | SEFTON, CRC CRIT. REF. BIOMED. ENG., vol. 14, 1987, pages 201 | "Medical Applications of Controlled Release", 1974, CRC PRES. | GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138 |